Heron Therapeutics, Inc. — 2023 Q1 Form 10-Q Summary
Business context and reporting period
Heron Therapeutics is a commercial-stage biotechnology company focused on acute-care and oncology products. The filing covers the three months ended March 31, 2023, compared with the three months ended March 31, 2022, and was filed May 11, 2023.
- Commercial products: CINVANTI, SUSTOL, ZYNRELEF and APONVIE.
- APONVIE became commercially available in the U.S. in March 2023.
- Development of HTX-034 was paused while the company focused on expanding ZYNRELEF’s U.S. indication.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Net product sales | $29.6 million | $23.5 million | 26.3% increase |
| Cost of product sales | $16.9 million | $11.4 million | 48.5% increase |
| Gross profit | $12.8 million | $12.1 million | 5.3% increase |
| Gross margin | 43.1% | 51.6% | Down 8.5 percentage points |
| Research and development | $13.8 million | $42.1 million | 56.3% decrease |
| General and administrative | $10.9 million | $9.5 million | 13.8% increase |
| Sales and marketing | $21.2 million | $23.4 million | 9.7% decrease |
| Loss from operations | $33.1 million | $62.9 million | 47.5% improvement |
| Net loss | $32.8 million | $63.9 million | 48.7% improvement |
| Basic and diluted loss per share | $0.27 | $0.63 | Improved |
| Net cash used in operating activities | $24.9 million | $43.9 million | 43.3% decrease |
- Estimated operating margin was negative 111.6%, compared with negative 268.2% in the prior-year quarter. Estimated net margin was negative 110.6%, compared with negative 272.4%.
- Product sales consisted of CINVANTI of $22.9 million, SUSTOL of $3.0 million, ZYNRELEF of $3.5 million and APONVIE of $0.2 million.
- Cost of product sales included a $5.3 million charge, primarily for writing off short-dated ZYNRELEF inventory.
- Cash and cash equivalents were $27.1 million and short-term investments were $32.9 million at March 31, 2023, for total cash, cash equivalents and short-term investments of approximately $60.0 million.
- Total assets were $220.9 million, total liabilities were $232.3 million and stockholders’ equity was negative $11.4 million.
- The company had $150.0 million principal amount of 1.5% senior unsecured convertible notes outstanding, with a carrying value of $149.3 million and maturity in May 2026.
- Investing activities provided $36.8 million, primarily from net maturities and sales of short-term investments. Financing activities used $0.2 million.
Material changes versus the prior comparable period
- Revenue increased 26.3%, led by higher CINVANTI, SUSTOL and ZYNRELEF sales and the initial APONVIE launch.
- Gross margin declined because product costs increased faster than revenue, including the ZYNRELEF inventory write-off.
- Research and development expense fell $28.3 million, primarily because of lower ZYNRELEF-related development costs and reduced personnel and stock-based compensation expense.
- General and administrative expense increased due to legal costs associated with CINVANTI patent litigation and support for activist shareholder activities.
- Sales and marketing expense declined primarily because of lower ZYNRELEF commercialization costs.
- Operating cash burn improved by $19.0 million year over year, although operations remained cash consumptive.
- In April 2023, the company changed its leadership structure and expects approximately $8.9 million of related severance and stock-based compensation expense, including $2.8 million primarily for severance and $6.1 million of non-cash stock-based compensation.
Guidance, outlook, risks, contingencies and unusual items
- The filing provides no clear numerical revenue, earnings or cash-flow guidance.
- Management stated that substantial doubt exists regarding the company’s ability to continue as a going concern for at least one year from the filing date. Additional financing may be required, and failure to obtain adequate funding could require reduced activities, personnel reductions or cessation of operations.
- Liquidity depends materially on commercial success, competitive products, manufacturing costs, the launches of ZYNRELEF and APONVIE, the potential expanded ZYNRELEF label, collaboration opportunities and general market conditions.
- The FDA accepted the supplemental application to broaden ZYNRELEF’s U.S. indication and assigned an October 23, 2023 PDUFA goal date.
- Fresenius Kabi is defending a CINVANTI patent infringement action after submitting an ANDA for a generic version. A five-day bench trial was scheduled for June 24, 2024; FDA approval of the ANDA may be restricted until the earlier of December 14, 2024 or resolution of the litigation.
- Three customers represented approximately 98.7% of Q1 product sales and 99.2% of accounts receivable, creating significant customer concentration.
- The company reported that it effectively had no available unissued and unreserved authorized common shares after considering outstanding shares and reserved shares. Stockholder approval was sought to increase authorized common shares from 150 million to 225 million and increase shares available under the equity incentive plan.
- Key risks include product adoption and reimbursement, generic and other competition, regulatory approvals and postmarketing requirements, manufacturing and supply constraints, intellectual-property protection, additional financing needs and potential shareholder dilution.
Important facts for investors to verify
- Whether APONVIE and ZYNRELEF achieve sufficient commercial growth to reduce the company’s cash burn.
- The FDA’s decision and timing regarding the expanded ZYNRELEF indication.
- The outcome and timing of the CINVANTI patent litigation and any potential generic entry.
- Available liquidity, financing activity and progress toward resolving the going-concern uncertainty.
- The amount and timing of leadership restructuring costs and any further restructuring actions.
- Trends in product gross margin, including the effect of manufacturing scale-up and potential inventory write-downs.
- Customer concentration and the company’s exposure to extended payment terms, returns, rebates and other product-sales allowances.
- Stockholder approval of the proposed increases in authorized shares and the resulting capacity for future equity financing or compensation awards.